CLINICAL AND SUBCLINICAL REACTIVATIONS OF VARICELLA-ZOSTER VIRUS IN IMMUNOCOMPROMISED PATIENTS
CLINICAL AND SUBCLINICAL REACTIVATIONS OF VARICELLA-ZOSTER VIRUS IN IMMUNOCOMPROMISED PATIENTS
复制标题
DOI：
10.1093/infdis/153.5.840
复制
发表时间：
1986-05-01
影响因子：
6.4
通讯作者：
WAHREN, B
中科院分区：
文献类型：
--
作者：
LJUNGMAN, P;LONNQVIST, B;WAHREN, B
免疫功能低下患者水痘带状疱疹病毒（VZV）引起的再活化疾病的频率通过抗体的酶联免疫吸附试验和淋巴细胞对VZV抗原的增殖反应来确定。在所有患者组中，亚临床再激活与经典带状疱疹一样常见。在骨髓移植（BMT）受者中，36%发生带状疱疹，26%发生亚临床再激活。诱导治疗期间白血病患者的相应频率分别为5%和10%;肾移植受者为0%和26%;恶性肿瘤患者分别为0%和6%。VZV的亚临床再活化因此似乎是严重免疫功能低下患者的常见发现。对VZV抗原的淋巴细胞增殖反应是BMT受者中VZV亚临床再激活的敏感指标。19例因VZV引起亚临床疾病的BMT受者中没有一人后来出现VZV的临床再激活。在BMT受者中，给予阿昔洛韦预防单纯疱疹病毒感染可减少治疗期间VZV临床和亚临床再激活的数量，但此后则不然。
The frequencies of reactivated disease due to varicella-zoster virus (VZV) in immunocompromised patients were determined by enzyme-linked immunosorbent assay for antibody and also by the lymphocyte proliferation response to VZV antigen. Subclinical reactivations were as common as classical herpes zoster in all patient groups. Among bone marrow transplant (BMT) recipients, 36% developed herpes zoster and 26%, a subclinal reactivation. The corresponding frequencies for patients with leukemia during induction therapy were 5% and 10%; in renal transplant recpients, 0% and 26%; and in patients with seminoma, 0% and 6%, respectively. Subclinical reactivation of VZV thus appears to be a common finding in severely immunocompromised patients. A regained lymphocyte proliferation response to VZV antigen is a sensitive indicator of subclinical reactivation of VZV in BMT recipients. None of 19 BMT recipients with subclinical disease due to VZV later developed clinical reactivation of VZV. Acyclovir given as prophylaxis against infection with herpes simplex virus reduced the number of clinical and subclinical reactivations of VZV during treatment in BMT recipients, but not thereafter.